Anavex Life Sciences (AVXL) Change in Receivables (2010 - 2019)
Anavex Life Sciences recorded quarterly Change in Receivables of $719245.0 in Q3 2019, up 4092.87% quarter-over-quarter from $17154.0 in Q2 2019, and up 206.45% year-over-year from $234699.0 in Q3 2018.
Anavex Life Sciences' Change in Receivables history runs 8 years deep, the most recent figure standing at $719245.0 for Q3 2019.
- In Q3 2019, Change in Receivables rose 206.45% year-over-year to $719245.0; the TTM figure through Sep 2019 stood at $772388.0 (up 234.23% YoY), while the FY2019 annual figure was $772388.0, up 234.23% from the prior year.
- Change in Receivables came in at $719245.0 for Q3 2019 at Anavex Life Sciences, up from $17154.0 in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $719245.0 in Q3 2019 to a low of -$37256.0 in Q2 2017.
- A 5-year average of $59472.2 and a median of $1333.0 in 2017 frame the typical range for Change in Receivables.
- On a YoY basis, Change in Receivables climbed as much as 15219.78% in 2018 and fell as far as 313.29% in 2018.
- Anavex Life Sciences' Change in Receivables stood at $15497.0 in 2015, then plunged by 294.99% to -$30217.0 in 2016, then soared by 92.15% to -$2371.0 in 2017, then sank by 313.29% to -$9799.0 in 2018, then surged by 7439.98% to $719245.0 in 2019.
- According to Business Quant data, Change in Receivables over the past three periods registered $719245.0, $17154.0, and $45788.0 for Q3 2019, Q2 2019, and Q1 2019 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 208,524.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -39.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -1.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 110.42 Mn |
| 10 | Anavex Life Sciences | 266.20 Mn | 134.45 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | 719,245.00 |
| Sep 30, 2019 | 719,245.00 |
| Jun 30, 2019 | 17,154.00 |
| Jun 30, 2019 | 17,154.00 |
| Mar 31, 2019 | 45,788.00 |
| Mar 31, 2019 | 45,788.00 |
| Dec 31, 2018 | -9,799.00 |
| Dec 31, 2018 | -9,799.00 |
| Sep 30, 2018 | 234,699.00 |
| Sep 30, 2018 | 234,699.00 |
| Jun 30, 2018 | 1,134.00 |
| Jun 30, 2018 | 1,134.00 |
| Mar 31, 2018 | -2,366.00 |
| Mar 31, 2018 | -2,366.00 |
| Dec 31, 2017 | -2,371.00 |
| Dec 31, 2017 | -2,371.00 |
| Sep 30, 2017 | 1,532.00 |
| Sep 30, 2017 | 1,532.00 |
| Jun 30, 2017 | -37,256.00 |
| Jun 30, 2017 | -37,256.00 |
| Mar 31, 2017 | 11,506.00 |
| Mar 31, 2017 | 11,506.00 |
| Dec 31, 2016 | -30,217.00 |
| Dec 31, 2016 | -30,217.00 |
| Sep 30, 2016 | 31,394.00 |
| Sep 30, 2016 | 31,394.00 |
| Jun 30, 2016 | -30,717.00 |
| Jun 30, 2016 | -30,717.00 |
| Mar 31, 2016 | -13,667.00 |
| Mar 31, 2016 | -13,667.00 |
| Dec 31, 2015 | 15,497.00 |
| Dec 31, 2015 | 15,497.00 |
| Jun 30, 2012 | -953.00 |
| Jun 30, 2012 | -953.00 |
| Mar 31, 2012 | -2,095.00 |
| Mar 31, 2012 | -2,095.00 |
| Dec 31, 2011 | 2,239.00 |
| Dec 31, 2011 | 2,239.00 |
| Sep 30, 2011 | -20,549.00 |
| Sep 30, 2011 | -20,549.00 |
| Jun 30, 2011 | 12,700.00 |
| Jun 30, 2011 | 12,700.00 |
| Mar 31, 2011 | 8,658.00 |
| Mar 31, 2011 | 8,658.00 |
| Dec 31, 2010 | -37,820.00 |
| Dec 31, 2010 | -37,820.00 |